Education
About Us
Working with TipRanks
Follow Us
Baxter International (BAX)
NYSE:BAX
BAX Stock Chart & Stats
$21.03
$0.05(0.17%)
At close: 4:00 PM EST
$21.03
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$17.40 - $37.74
Previous CloseN/A
Volume899.70K
Average Volume (3M)7.10M
Market Cap
$10.21B
Enterprise Value$18.80B
Total Cash (Recent Filing)$1.73B
Total Debt (Recent Filing)$9.71B
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 12, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)0.69
Shares Outstanding514,055,800
10 Day Avg. Volume7,713,184
30 Day Avg. Volume7,101,588
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.14
Price to Sales (P/S)1.40
P/FCF Ratio26.60
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit4.82
Enterprise Value/Ebitda18.30
Forecast
1Y Price Target
$22.14Price Target Upside5.28% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)2.27
Revenue Forecast (FY)$11.30B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Capital AllocationA dividend reduction framed as part of a deleveraging push creates room to strengthen the balance sheet and improve financial flexibility.
Earnings PerformanceAn adjusted EPS result that beat consensus suggests underlying operational resilience and supports the case for future positive earnings surprises.
Leadership And Strategic DirectionCEO Andrew Hider's announced action plan to stabilize the business and boost operational efficiency signals decisive leadership likely to drive strategic improvements.
Bears Say
Margin PressureAdjusted gross and operating margins falling short of expectations point to profitability pressures that may require either cost actions or improved product mix to reverse.
Operational HeadwindsOngoing issues such as a shipment hold and demand weakness in hospital IV and premix channels represent persistent headwinds that could constrain recovery in core markets.
Revenue Guidance And Growth RiskReduced sales growth and trimmed EPS guidance raise doubts about the company's ability to sustain prior growth trajectories and satisfy investor expectations.
Baxter International News
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $17.40 and its highest was $37.74 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $10.21B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Feb 12, 2026 which is in 7 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Oct 30, 2025. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.598 by $0.092.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.75%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.54.
How many shares outstanding does Baxter International have?
Baxter International has 514,055,800 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.69 in its last earnings report, beating expectations of $0.598. Following the earnings report the stock price went down -14.544%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.14 (5.28% Upside)
$22.14 (5.28% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.93%
12-Months-Change
Fundamentals
Return on Equity
-4.70%
Trailing 12-Months
Asset Growth
-21.03%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Baxter International's earnings call highlighted revenue growth in key segments, particularly in Advanced Surgery and Healthcare Systems & Technologies. However, significant challenges exist, notably with the Infusion Therapies and Pharmaceuticals segments, as well as the decision to reduce the dividend for deleveraging purposes. The company's focus on stabilizing business operations, improving the balance sheet, and driving continuous improvement reflects a proactive approach to addressing these challenges.View all BAX earnings summariesBAX Net sales Breakdown
48.96% Medical Products and Therapies
27.75% Healthcare Systems and Technologies
22.67% Pharmaceuticals
0.63% Other
BAX Stock 12 Month Forecast
Average Price Target
$22.14
▲(5.28% Upside)
Technical Analysis
Ownership Overview
0.35% Insiders
34.11% Mutual Funds
2.18% Other Institutional Investors
36.22% Public Companies and
Individual Investors